Il DOTT. F. SIRAGUSA SEGNALA: “Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease”
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Key Points Question Among sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and sulfonylureas, which class of oral antidiabetic drugs (OADs) is the preferred therapeutic option for patients with both nonalcoholic fatty liver disease (NAFLD) and type...